{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:28:33Z","timestamp":1791332913414,"version":"4.3.1"},"reference-count":30,"publisher":"Rockefeller University Press","issue":"13","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,20]]},"abstract":"<jats:p>Chronic HTLV-I (human T cell lymphotropic virus type I) infection may cause adult T cell leukemia\/lymphoma (ATL), a disease with dismal long-term prognosis. The HTLV-I transactivator, Tax, initiates ATL in transgenic mice. In this study, we demonstrate that an As2O3 and IFN-\u03b1 combination, known to trigger Tax proteolysis, cures Tax-driven ATL in mice. Unexpectedly, this combination therapy abrogated initial leukemia engraftment into secondary recipients, whereas the primary tumor bulk still grew in the primary hosts, only to ultimately abate later on. This loss of initial transplantability required proteasome function. A similar regimen recently yielded unprecedented disease control in human ATL. Our demonstration that this drug combination targeting Tax stability abrogates tumor cell immortality but not short-term growth may foretell a favorable long-term efficiency of this regimen in patients.<\/jats:p>","DOI":"10.1084\/jem.20101095","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T06:20:13Z","timestamp":1291702813000},"page":"2785-2792","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":88,"title":["Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia"],"prefix":"10.1084","volume":"207","author":[{"given":"Hiba","family":"El Hajj","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"El-Sabban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162 8640, Japan 4"},{"name":"Centre for Research in Infectious Diseases, School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Zaatari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ablain","sequence":"additional","affiliation":[{"name":"Service de Biochimie, Equipe labellis\u00e9e, Ligue Nationale Contre le Cancer, Centre National de la Recherche Scientifique\/Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 Mixte de Recherche 7212, Unit\u00e9 944 6 and 7"},{"name":"Service de Pathologie, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 728, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Saint Louis, 75475 Paris, Cedex 10, France 6 and 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrazad T.","family":"Saab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Janin","sequence":"additional","affiliation":[{"name":"Service de Biochimie, Equipe labellis\u00e9e, Ligue Nationale Contre le Cancer, Centre National de la Recherche Scientifique\/Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 Mixte de Recherche 7212, Unit\u00e9 944 6 and 7"},{"name":"Service de Pathologie, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 728, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Saint Louis, 75475 Paris, Cedex 10, France 6 and 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihab","family":"Nasr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Kfoury","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nicot","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine 8 , 9 , and 10"},{"name":"University of Kansas Cancer Center 8 , 9 , and 10"},{"name":"Center for Viral Oncology, University of Kansas Medical Center, Kansas City, KS 66160 8 , 9 , and 10"},{"name":"Department of Pathology and Laboratory Medicine 8 , 9 , and 10"},{"name":"University of Kansas Cancer Center 8 , 9 , and 10"},{"name":"Center for Viral Oncology, University of Kansas Medical Center, Kansas City, KS 66160 8 , 9 , and 10"},{"name":"Department of Pathology and Laboratory Medicine 8 , 9 , and 10"},{"name":"University of Kansas Cancer Center 8 , 9 , and 10"},{"name":"Center for Viral Oncology, University of Kansas Medical Center, Kansas City, KS 66160 8 , 9 , and 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie, Equipe labellis\u00e9e, Ligue Nationale Contre le Cancer, Centre National de la Recherche Scientifique\/Universit\u00e9 Paris Descartes Unit\u00e9 Mixte de Recherche 8147, H\u00f4pital Necker\u2013Enfants Malades, 75015 Paris, Cedex 15, France 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hall","sequence":"additional","affiliation":[{"name":"Centre for Research in Infectious Diseases, School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"de Th\u00e9","sequence":"additional","affiliation":[{"name":"Service de Biochimie, Equipe labellis\u00e9e, Ligue Nationale Contre le Cancer, Centre National de la Recherche Scientifique\/Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 Mixte de Recherche 7212, Unit\u00e9 944 6 and 7"},{"name":"Service de Pathologie, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale\/Universit\u00e9 Paris Diderot Unit\u00e9 728, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Saint Louis, 75475 Paris, Cedex 10, France 6 and 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1 , 2 , and 3"},{"name":"Department of Human Morphology 1 , 2 , and 3"},{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon 1 , 2 , and 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2010,12,6]]},"reference":[{"key":"2023072617133356800_bib1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1098\/rstb.2000.0638","article-title":"Is human T-cell lymphotropic virus type I really silent?","volume":"355","author":"Asquith","year":"2000","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2023072617133356800_bib2","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2009-10-246959","article-title":"Adult T-cell leukemia\/lymphoma development in HTLV-1-infected humanized SCID mice","volume":"115","author":"Banerjee","year":"2010","journal-title":"Blood."},{"key":"2023072617133356800_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","article-title":"Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells","volume":"93","author":"Bazarbachi","year":"1999","journal-title":"Blood."},{"key":"2023072617133356800_bib4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(04)01608-0","article-title":"New therapeutic approaches for adult T-cell leukaemia","volume":"5","author":"Bazarbachi","year":"2004","journal-title":"Lancet Oncol."},{"key":"2023072617133356800_bib5","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1182\/blood-2008-08-077941","article-title":"Stem cell concepts renew cancer research","volume":"112","author":"Dick","year":"2008","journal-title":"Blood."},{"key":"2023072617133356800_bib6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0959-437X(02)00018-7","article-title":"The core-binding factor leukemias: lessons learned from murine models","volume":"13","author":"Downing","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2023072617133356800_bib7","first-page":"2849","article-title":"Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation","volume":"96","author":"El-Sabban","year":"2000","journal-title":"Blood."},{"key":"2023072617133356800_bib8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature."},{"key":"2023072617133356800_bib9","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1158\/0008-5472.CAN-07-0972","article-title":"Mixed lineage leukemia translocations and a leukemia stem cell program","volume":"67","author":"Faber","year":"2007","journal-title":"Cancer Res."},{"key":"2023072617133356800_bib10","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","article-title":"Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine","volume":"332","author":"Gill","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"2023072617133356800_bib11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nm1389","article-title":"Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I","volume":"12","author":"Hasegawa","year":"2006","journal-title":"Nat. Med."},{"key":"2023072617133356800_bib12","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","article-title":"Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa","volume":"332","author":"Hermine","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"2023072617133356800_bib13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/sj.thj.6200374","article-title":"Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"5","author":"Hermine","year":"2004","journal-title":"Hematol. J."},{"key":"2023072617133356800_bib14","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072617133356800_bib15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3324\/haematol.10703","article-title":"Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"92","author":"Ishitsuka","year":"2007","journal-title":"Haematologica."},{"key":"2023072617133356800_bib16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature."},{"key":"2023072617133356800_bib17","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL)","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood."},{"key":"2023072617133356800_bib18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1142596","article-title":"Tumor growth need not be driven by rare cancer stem cells","volume":"317","author":"Kelly","year":"2007","journal-title":"Science."},{"key":"2023072617133356800_bib19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2008.12.012","article-title":"Curing APL: differentiation or destruction?","volume":"15","author":"Kogan","year":"2009","journal-title":"Cancer Cell."},{"key":"2023072617133356800_bib20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1084\/jem.193.12.1361","article-title":"Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML\/retinoic acid receptor \u03b1 degradation","volume":"193","author":"Lallemand-Breitenbach","year":"2001","journal-title":"J. Exp. Med."},{"key":"2023072617133356800_bib21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"2023072617133356800_bib22","doi-asserted-by":"publisher","first-page":"10984","DOI":"10.1073\/pnas.190167297","article-title":"Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice","volume":"97","author":"Lavau","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023072617133356800_bib23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat. Rev. Cancer."},{"key":"2023072617133356800_bib24","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2002-09-2986","article-title":"Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells","volume":"101","author":"Nasr","year":"2003","journal-title":"Blood."},{"key":"2023072617133356800_bib25","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2005-09-3572","article-title":"Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation","volume":"107","author":"Nasr","year":"2006","journal-title":"Blood."},{"key":"2023072617133356800_bib26","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm.1891","article-title":"Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation","volume":"14","author":"Nasr","year":"2008","journal-title":"Nat. Med."},{"key":"2023072617133356800_bib27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.V98.4.1200","article-title":"The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors","volume":"98","author":"Portis","year":"2001","journal-title":"Blood."},{"key":"2023072617133356800_bib28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature."},{"key":"2023072617133356800_bib29","first-page":"2565","article-title":"Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element","volume":"11","author":"Stadler","year":"1995","journal-title":"Oncogene."},{"key":"2023072617133356800_bib30","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1073\/pnas.94.8.3978","article-title":"Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia","volume":"94","author":"Zhu","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/207\/13\/2785\/1778039\/jem_20101095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/207\/13\/2785\/1778039\/jem_20101095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T20:07:52Z","timestamp":1690402072000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/207\/13\/2785\/40805\/Therapy-induced-selective-loss-of-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,6]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,12,20]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20101095","relation":{},"ISSN":["1540-9538","0022-1007"],"issn-type":[{"value":"1540-9538","type":"electronic"},{"value":"0022-1007","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,6]]}}}